How a condition is named can be just as consequential as how it is treated — particularly in prostate pathology, where overtreatment of indolent tumors remains a persistent clinical burden. The language physicians use at diagnosis shapes patient psychology and, ultimately, the interventions patients request. A randomized online experiment published in the Journal of the National Cancer Institute quantifies precisely how much that labeling effect matters for low-risk prostate disease.
Across 2,775 Australians aged 50 and older — both males with prostates and female partners of affected males — participants were randomized to receive one of three diagnostic labels: the conventional "low-risk prostate cancer, Gleason Group 1," or the softer alternatives "low-risk prostate neoplasm" or "low-risk prostate lesion." A second randomization varied the depth of benefit-to-harms information about management options. The primary outcome was preference for curative-intent treatment (prostatectomy or radiation) versus conservative management (active surveillance or PSA monitoring). The "lesion" label reduced preference for curative-intent treatment most markedly in females within low-information conditions, with a risk difference of -11.6 percentage points. The "neoplasm" label produced smaller but directionally consistent reductions across both sexes. Importantly, providing high-quality benefit-harms information independently shifted preferences away from curative-intent approaches, suggesting informational context moderates the labeling effect.
This work enters a well-established but still-evolving debate: the 2013 NCI expert panel famously recommended retiring the term "cancer" for certain low-risk indolent lesions, yet adoption in clinical practice has stalled. The current study adds causal — not merely correlational — evidence that terminology meaningfully influences patient decision-making, even after controlling for information quality. The key limitation is the hypothetical nature of the experiment; whether these label-driven preference shifts translate into actual clinical choices at the point of care remains untested. The moderate effect sizes also suggest labeling alone is insufficient — paired benefit-harms counseling may be necessary for durable reductions in overtreating indolent disease. Incrementally confirmatory overall, but the gender-stratified findings introduce a nuance that clinical communicators should not overlook.